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Mesangial expression of intercellular adhesion molecule-i in primary
glomeruloaclerosis. Frozen sections of renal biopsy specimens from eight
patients with primary focal segmental glomeruloscierosis (FSGS) and 10
patients with membranous nephropathy (MN) were stained in immuno-
peroxidase with the intercellular adhesion molecule-I (ICAM-l) monoclo-
nal antibody (MoAb), CL203.4. ICAM-l was expressed by mesangial cells
in six patients with FSGS. On the other hand, ICAM-l was not detected in
mesangial cells in patients with MN or in the non-affected portion of
tumoral kidneys used to control normal renal expression of ICAM- I. Dc
novo mesangial expression of ICAM-l in FSGS suggests that sclerosis
results from an inflammatory process, possibly associated with local
release of cytokines.
Focal segmental glomerulosclerosis (FSGS) is a cause of
nephrotic syndrome and progressive renal failure in humans.
The etiology and pathogenesis of FSGS are obscure. Until now,
in fact, whether sclerosis is secondary to an inflammatory process
or to other mechanisms, such as genetic factors and alteration
in glomerular hemodynamics [11, has not been examined.
To assess the role of inflammatory processes in the patho-
genesis of FSGS, we have investigated the expression of
intercellular adhesion molecule (ICAM-l) in renal biopsies from
patients with FSGS, since in vitro experiments suggest that this
molecule may play a major role in inflammation by mediating
leukocyte adherence and emigration [2, 3]. ICAM-l is a cell
surface molecule that facilitates interaction between leukocytes
and recruitment of leukocytes at sites of inflammation [4, 5].
The expression of ICAM-l is up-regulated by cytokines, such
as immune interferon, interleukin-l, and tumor necrosis factor
[6j. Recently, it has been shown that the de novo expression of
ICAM-l occurs on tubular cells of transplanted kidney during
rejection [7, 8].
In this study, we show that ICAM-1 is abnormally expressed
on mesangial cells of glomeruli affected by FSGS. This finding
indicates that an inflammatory process, possibly mediated by
cytokines, is associated with FSGS.
Methods
Patients
Eight adult patients with primary FSGS and 10 patients with
membranous nephropathy (MN) were retrospectively selected
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among those submitted to renal biopsy in our renal units. At the
time of biopsy, in all patients renal function was well preserved
(creatinine clearance was higher than 80 ml/min), proteinuria
was in the nephrotic range (higher than 21 g/week), and no
immunosuppressive treatment was administered.
In two patients with renal cell carcinoma the tumoral kidney
was surgically excised and unaffected areas were used to
control the normal renal expression of ICAM-l.
Monoclonal antibodies and conventional antisera
The anti-ICAM-l MoAb CL203.4 was developed and char-
acterized as described elsewhere [9, 101. The murine anti-
idiotypes MoAb MT1.1 and MT1.34 were developed in the
laboratory of one of the authors (S.F.) with the hybridoma
technique [111. The hybridomas secreting MT1.l and MT1.34
were constructed with splenocytes from BALB/c mouse immu-
nized with the syngeneic anti-ICAM-l MoAb CL203.4.MTi.l
recognizes an idiotype within the antigen combining site of
CL203.4, as shown by inhibition of binding of CL203.4 to
ICAM-i. MTI.34 recognizes an idiotype outside the antigen
combining site of MoAb CL203.4 and does not inhibit its
binding to ICAM-l. Biotinylated rabbit anti-mouse Ig antibod-
ies were purchased from DAKO (Copenhagen, Denmark).
Indirect immunoperoxidase
Three-micron thick sections, frozen cut and fixed in 4%
buffered formalin were sequentially incubated with MoAb
CL203.4 and biotinylated antimurine Ig xenoantibodies. Fixa-
tion in formalin is necessary to achieve adequate optical defi-
nition. Long fixation time may impair the efficacy of MoAb
CL203.4; preliminary experiments, however, showed that the
activity of MoAb CL203.4 is preserved after a five minute
fixation. Sections from an inflamed tonsil were used as the
positive control of staining. Tissue sections incubated with
normal mouse serum instead of primary antibody were used as
negative control.
Blocking studies
These studies were performed in sections of frozen normal
renal tissue to prove the specificity of the anti-ICAM-1 MoAb
CL203.4. In these studies MTI.1 substituted for ICAM-1, being
an internal image of ICAM-l [121. The blocking of CL203.4 by
MTI.l was proved either by pre-mixing (1:1) undiluted aliquots
of CL203.4 and MTI.i and incubating the tissue with the
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Fig. 1. (A). Expression ofICAM-1 in normal renal tissue. The MoAb CL203.4 diffusely stains in immunoperoxidase glomerular endothelial cells
(brown color; x240). (B). At higher power photo (x580), note the absence of staining in mesangial areas.
Fig. 2. Blocking studies. A. The MoAb CL203.4 stains glomerular cells. . In another section of the same glomerulus shown in photo 2A, the
antiidiotype MoAb MT1.1 (an internal image of ICAM-l) displaces the CL203.4 MoAb from its binding to ICAM-l on glomerular cells.
mixture, or by incubation of the tissue with CL203.4 followed
after 30 minutes by incubation with MT1.l. The control con-
sisted of incubation of the tissue with CL203.4 alone, a mixture
(1:1) of undiluted aliquots of CL203,4 and MT1.34, or saline.
After any incubation steps of 30 minutes, the sections were
washed three times with PBS,
Glomerular monocyte/macrophage cells
To understand whether ICAM- 1 was expressed in monocyte/
macrophage cells within the glomeruli of patients with FSGS,
sections from renal biopsies were cut sequentially and were
alternatively stained with pararosaniline for istochemical dem-
onstration of estherase [13] or immunostained with CL203.4 as
previously described. Monocyte/macrophage cells, but not res-
ident mesangial cells are estherase-positive; thus, the finding of
an estherase-positive cell in a mesangial area and of a cell
expressing ICAM-l in the same area in the next section
indicates that ICAM-l is expressed on a monocyte.
Semiquantitative grade of staining
The grade of staining was independently evaluated by three
authors in glomeruli, tubules, renal interstitium and vessels
(venules, arterioles). Three grades (from 0 to 2) were assigned
to the intensity of staining according to the following arbitrary
scores: 0 = staining equal to negative control; 1 = staining
present but less intense than positive control; 2 staining
present with the same or higher intensity than in positive
control. The mean grade was calculated by averaging grades
assigned by single authors and approximating the arithmetical
mean to the nearest unity.
Statistics
Fisher's exact test was used to compare the percent positivity
of ICAM-l expression in patients with FSGS versus patients
with MN.
Results
Expression of ICAM-1 in normal renal tissue
In normal renal tissue, ICAM-l was expressed by glomerular
capillary endothelial cells, but not by glomerular epithelial nor
mesangial cells (Fig. 1). The expression on glomerular endothe-
hum was grade 1, and was diffuse (that is, present in all
glomeruli) and segmental (present in only a portion of the
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Fig. 3. A. Segmental expression of ICAM-l (brown stained areas) on endothelial and mesangial ce/Is of FSGS (x232). B. Higher power photo
(x580) of the same glomerulus of photo A, showing the mesangial localization of ICAM-1.
Fig. 4. Absence of glomerular estherase-positive cells in FSGS (estherase normally stains tubular cells and monocytes).
Fig. 5. Expression of ICAM-! on endothelial cells of MN (brown stained areas; x236). Note the absence of staining in the mesangial areas.
Table 1. Glomerular expression of ICAM- 1 in FSGS
Patient Epithelium
Endothelium
%
Mesangium
%
P. G.
M.M.
C.M.
PG.
D, G.
I. L.
M. G.
C. M.
0
0
0
0
0
0
0
0
1(80)
0
0
1(71)
2 (40)
1 (33)
2 (100)
2 (100)
2 (60)
2(75)
0
0
1 (40)
1 (100)
2 (100)
2 (60)
The numbers out of parenthesis are the grade of staining, quantitated
as described in Methods. The percent numbers in parenthesis indicate
the percent of total glomeruli expressing ICAM- 1.
glomerulus). Neither proximal nor distal tubules expressed
ICAM-l. ICAM-l was present on endothelial cells in a limited
number of interstitial capillaries and venules, but not in arteri-
oles.
Blocking studies
The incubation of sections of normal renal tissue with a
mixture of CL203.4 and MTL34, or with CL203.4 followed by
MT1 34 was followed by the pattern of staining obtained by
incubating normal renal tissue alone, that is, diffuse staining of
glomerular endothelium (Fig. 2A). The incubation of the tissue
with MT1.l either pre-mixed with CL2034 or 30 minutes after
incubation with CL203.4 displaced CL203.4 from its binding
with ICAM-l (Fig. 2B).
Expression of ICAM-I in FSGS
Glomeruli. The glomerular expression of ICAM-l in FSGS is
shown in Figure 3 and the grade of staining is summarized in
Table 1. ICAM-! was expressed by glomerular capillary endo-
thelial cells in six patients, in three with grade 1 and in three
with grade 2 of staining. The staining pattern was focal segmen-
tal in four patients, and diffuse segmental in two patients.
ICAM-l was expressed by mesangial cells in six patients, in two
with grade I and in four with grade 2 of staining. The distribu-
tion was focal segmental in four patients, diffuse segmental in
two. ICAM-1 was never expressed on epithelial cells.
Tubules. ICAM-l was expressed with a focal distribution,
grade 1, by proximal tubular cells in three patients. No staining
was seen in distal tubules in any patients.
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Table 2. Glomerular expression of ICAM-1 in MN
Patient
Epithelium
%
Endothelium
% Mesangium
R.A. 0 1(80) 0
M.M. 0 0(100) 0
LB. 0 0(100) 0P.L. 0 0 0
B.A. 0 0(100) 0
C.G. 0 0 0
1. B. 1(25) 1(71) 0
M.L. 0 1(100) 0
A. 0. 1(20) 1(100) 0
M.G. 0 1(100) 0
The numbers out of parenthesis are the grade of staining, quantitated
as described in Methods. The percent numbers in parenthesis indicate
the percent of total glomeruli expressing ICAM-l.
Interstitium, arterioles and venules. ICAM-l was expressed
by a few interstitial cells in four patients. Furthermore, ICAM-1
was expressed by endothelial cells in venules, but not in
arterioles.
Glomerular inonocyte/macrophage cells in FSGS
Sequential sections of renal biopsy tissue from patients with
FSGS did not demonstrate estherase positive cells in mesangial
areas that stained with the anti-ICAM MoAb CL203.4. Actu-
ally, no glomerular estherase positive cells were observed at all
in FSGS (Fig. 4).
Expression of ICAM-1 in MN
Glotneruli. The glomerular expression of ICAM- 1 in MN is
shown in Figure 5, and the grade of staining is summarized in
Table 2. ICAM-l was expressed on glomerular capillary endo-
thelial cells in eight patients (grade I); in two patients the
distribution was focal segmental, in six patients it was diffuse.
ICAM-l was expressed by isolated parietal epithelial cells
(grade 1) in two patients. No stain was observed in visceral
epithelial cells. No expression of ICAM-l was observed in the
mesangium in any patient.
Tubules. ICAM-l was focally expressed both on proximal
and distal tubular cells in four patients (grade I). In one further
patient the tubular expression of ICAM- 1 was diffuse (grade 1).
Interstitium and vessels. ICAM-l was expressed by a few
constitutive interstitial cells (grade 1) in 2 patients. ICAM- 1 was
present in venules, and in arteriolar endothelial cells in two
patients (grade 1).
Discussion
In this study we have used the monoclonal antibody CL203.4
to detect the expression of ICAM-l in frozen renal tissue, The
specificity of this antibody for ICAM-! has been previously
documented [9, 101, and we have further proved it in our
experimental conditions by blocking experiments. We have
shown, in fact, that CL203.4 was displaced by MTI.l, an
anti-idiotype that recognizes an idiotype within the combining
site of CL203.4 and is, therefore, an internal image of ICAM-l
[12].
Immunostaining with CL203.4 has confirmed the previous
finding of others [7, 8, 10] that in normal renal tissue ICAM-l is
expressed on endothelial cells of glomerular capillaries, but not
on mesangial or epithelial glomerular cells. The normal distri-
bution of ICAM- 1 in glomerular endothelium is maintained in
kidneys from patients with FSGS and MN. Furthermore, we
have shown for the first time that ICAM- 1 is expressed by
mesangial cells in patients with FSGS. To understand whether
the ICAM- 1 positive cells present in the mesangium of these
patients were resident mesangial cells, or infiltrating mono-
cytes, we have looked for estherase positive cells in the
glomeruli. The positivity for estherase, in fact, is characteristic
of monocyte/macrophage cells [13]. No estherase positive cells
were detected in the glomeruli of our patients with FSGS; this
does not exclude that monocytes may rarely be found in
glomeruli with FSGS [14], but is sufficient to exclude that in our
renal biopsy samples the ICAM- 1 positive mesangial cells were
monocytes.
In FSGS, the pattern of distribution of ICAM-l positive cells
in the mesangium was always segmental; the grade of staining
was very intense in four cases, as it was comparable to that seen
in an inflamed tonsil with strong staining of both lymphoid/
macrophage cells and endothelial cells of venules. The expres-
sion of ICAM- 1 by mesangial cells does not appear to be caused
by proteinuria or other nonspecific effects of glomerular dis-
ease, since ICAM- 1 was not detected on mesangial cells in renal
biopsies from patients with MN having similar levels of pro-
teinuria, and renal function (percent expression of ICAM-l in
FSGS vs. MN) was significantly different at the 0.001 level with
Fisher's text.
Our study does not define the mechanism responsible for the
mesangial expression of ICAM-1 in FSGS. In vitro studies have
shown that the expression of ICAM-l in different cell types is
caused by exposure to cytokines, such as interferon gamma,
interleukin-1 (IL-i), and TNF [6]. In addition, we know that
mesangial cells can release both IL-i and TNF [15, 16]. These
findings suggest that the mesangial expression of ICAM-! in
FSGS is secondary to the local effect of inflammatory cyto-
kine(s), possibly released by resident mesangial cells, It is of
interest that the glomerular production of IL-i is increased in a
toxic model of focal segmental glomerulosclerosis in the rat
[17].
It has been shown that mesangial cells can increase matrix
and collagen synthesis when exposed to a variety of stimuli,
including interleukin-I [18]. Lovett et al recently showed that
mesangial cells stimulated by interleukin-! undergo transforma-
tion with the production of their own IL- 1; this change can
result in a self-sustaining cycle of stimulation [19]. Thus, we
hypothesize that in FSGS local release of interleukin-l, wit-
nessed by the de novo expression of ICAM-1, results in
continued stimulation of mesangial cells and consequent syn-
thesis of mesangial matrix, leading to mesangial sclerosis.
In conclusion, our study shows that in FSGS ICAM-1 is
expressed on glomerular mesangial cells. This finding does not
definitely indicate a role of ICAM-1 in the pathogenesis and
progression of the disease. The de novo expression of ICAM-l,
however, indicates activation of mesangial cells, possibly by
cytokines, and gives indirect evidence that an inflammatory
step leads to the silent wasteland of sclerosis in human FSGS.
Reprint requests to Prof A. Dal Canton, Cattedra di Nefrologia,
Policlinico Materdornini, Via Campanella, 88100 Catanzaro, Italy.
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